Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@KraneShares](/creator/twitter/KraneShares)
"Chinas NMPA has approved Sino Biopharmaceutical subsidiary LaNova to begin Phase II clinical trials for a new drug that is showing promise in battling cancer. It does this by enhancing anti-tumor activity through the redirection of immune cells to tumor microenvironments"  
[X Link](https://x.com/KraneShares/status/1961193582229913807) [@KraneShares](/creator/x/KraneShares) 2025-08-28T22:26Z 5807 followers, 6131 engagements


"Meituans food delivery company Keeta has launched its services in Kuwait the third country in the Middle East its entered after Saudi Arabia and Qatar. At present Meituan handles over XXX million orders every day for more than XXX million users"  
[X Link](https://x.com/KraneShares/status/1974146257128927678) [@KraneShares](/creator/x/KraneShares) 2025-10-03T16:15Z 5808 followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@KraneShares "Chinas NMPA has approved Sino Biopharmaceutical subsidiary LaNova to begin Phase II clinical trials for a new drug that is showing promise in battling cancer. It does this by enhancing anti-tumor activity through the redirection of immune cells to tumor microenvironments"
X Link @KraneShares 2025-08-28T22:26Z 5807 followers, 6131 engagements

"Meituans food delivery company Keeta has launched its services in Kuwait the third country in the Middle East its entered after Saudi Arabia and Qatar. At present Meituan handles over XXX million orders every day for more than XXX million users"
X Link @KraneShares 2025-10-03T16:15Z 5808 followers, XXX engagements

creator/twitter::427479070/posts
/creator/twitter::427479070/posts